Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Patient Preference for Subcutaneous vs. Intravenous Immune Therapy — Stella

Recruiting

Back to Renal Cell Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

Diwakar Davar

Enrollment target

~880 participants

Started

November 2025

Primary completion

November 2030

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov